Accordingly indian scientists are working hard to find out the vaccine for the deadly coronavirus which is claiming the lives of many people across the globe. COVAXIN, India's first potential Covid19 vaccine has been given DCGI (Drug Controller General of India) approval for Phase I and II human clinical trials that are going to start from July and the vaccine is developed by Hyderabad-based Bharat Biotech, in association with ICMR (Indian Council for Medical Research). It is said that the SARS-Cov-2 strain was isolated in NIV, pune and transferred to Bharat Biotech. The inactivated vaccine which was developed at Bharat Biotech Company, hyderabad has shown positive results in preclinical studies.

Meanwhile Dr krishna Ella, Chairman and Managing director, Bharat Biotech said that, "We are proud to announce COVAXIN, India’s first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine. The proactive support and guidance from CDSCO have enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform.”

Perhaps india, one of the leading manufacturers of vaccines and generic medicines is surely going to play an important role in the development of coronavirus vaccine as numerous pharma companies are working on different drugs. According to the WHO data, 10 vaccine candidates have entered the human trial state. Earlier in May, the government said that there are about 30 groups who are trying to develop a vaccine and some companies are in late pre-clinical stage. Vijayraghavan, who is also co-chair of the government’s covid-19 task force on scientific development said that "The world is investing in more than 100 vaccines as covid-19 is a new disease and we have to get a vaccine as soon as possible. The entire process will cost $2-3 billion."